Trimetazidine improves hepatic lipogenesis and steatosis in non‑alcoholic fatty liver disease via AMPK‑ChREBP pathway

Zhang,Ying; Li,Can; Li,Xiuqi; Wu,Cheng; Zhou,Haiyan; Lu,Shuang; Liu,Xingde

doi:10.3892/mmr.2020.11309

Trimetazidine improves hepatic lipogenesis and steatosis in non‑alcoholic fatty liver disease via AMPK‑ChREBP pathway

Authors:
- Ying Zhang
- Can Li
- Xiuqi Li
- Cheng Wu
- Haiyan Zhou
- Shuang Lu
- Xingde Liu
View Affiliations

Affiliations: Department of Cardiology, General Hospital of The Yangtze River Shipping, Wuhan, Hubei 430010, P.R. China, Department of Infectious Diseases, Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou 550004, P.R. China, Department of Cardiology, Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou 550004, P.R. China, Department of Clinical Research Centre, Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou 550004, P.R. China, Department of Cardiology, The Second Clinical Medical College of Guiyang College of Chinese Medicine, Guiyang, Guizhou 550004, P.R. China
Published online on: July 8, 2020 https://doi.org/10.3892/mmr.2020.11309
Pages: 2174-2182
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Clinical studies have demonstrated that trimetazidine (TMZ) possesses a synergistic hypolipidemic effect together with statins, but the underlying mechanism remains to be elucidated. The present study aimed to investigate the role of TMZ in non‑alcoholic fatty liver disease (NAFLD). By investigating the TMZ treatment of NAFLD, it was identified that high‑fat diet (HFD) mice exhibit significant changes in several physiologic indices, including body weight, plasma lipids and glucose tolerance. Notably, hepatocyte bullous steatosis and fibrosis in HFD mice are greatly attenuated by 8 weeks of TMZ treatments. The results of the present study also indicated that the expression of carbohydrate‑responsive element‑binding protein (ChREBP), fatty acid synthase and acetyl‑CoA carboxylase were all significantly reduced in the HFD + TMZ group compared with the HFD group. In order to confirm the hypothesis in vitro, the palmitate‑treated liver cancer cell line (HepG2) was employed and similar results were obtained in TMZ‑treated HepG2 cells. Furthermore, TMZ markedly upregulated the AMP‑activated protein kinase (AMPK) signaling pathway and reduced the expression of forkhead box O1 (FOXO1) in the cells, while these effects controlled by TMZ were abolished by the AMPK inhibitor Compound C. The present study reported that knockdown of FOXO1 expression by FOXO1 small interfering RNA resulted in a reduction of ChREBP protein expression and post‑transcriptional activity. In summary, for the first time, to the best of the authors' knowledge, the present study revealed a novel role of TMZ in hepatic steatosis; TMZ ameliorated ChREBP‑induced de novo lipogenesis by activating the AMPK‑FOXO1 pathway.

View Figures

View References

1	Yki-Järvinen H: Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol. 2:901–910. 2014. View Article : Google Scholar : PubMed/NCBI
2	Malik VS, Willett WC and Hu FB: Global obesity: Trends, risk factors and policy implications. Nat Rev Endocrinol. 9:13–27. 2013. View Article : Google Scholar : PubMed/NCBI
3	Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart J-C, James WPT, Loria CM and Smith SC Jr; International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity, : Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 120:1640–1645. 2009. View Article : Google Scholar : PubMed/NCBI
4	Wong VW-S: Nonalcoholic fatty liver disease in Asia: A story of growth. J Gastroenterol Hepatol. 28:18–23. 2013. View Article : Google Scholar : PubMed/NCBI
5	Lazo M, Hernaez R, Eberhardt MS, Bonekamp S, Kamel I, Guallar E, Koteish A, Brancati FL and Clark JM: Prevalence of nonalcoholic fatty liver disease in the United States: The Third National Health and Nutrition Examination Survey, 1988–1994. Am J Epidemiol. 178:38–45. 2013. View Article : Google Scholar : PubMed/NCBI
6	Marengo A, Jouness RIK and Bugianesi E: Progression and natural history of nonalcoholic fatty liver disease in adults. Clin Liver Dis. 20:313–324. 2016. View Article : Google Scholar : PubMed/NCBI
7	Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M and Sanyal AJ; American Gastroenterological Association; American Association for the Study of Liver Diseases; American College of Gastroenterologyh, : The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 142:1592–1609. 2012. View Article : Google Scholar : PubMed/NCBI
8	Jaswal JS, Keung W, Wang W, Ussher JR and Lopaschuk GD: Targeting fatty acid and carbohydrate oxidation--a novel therapeutic intervention in the ischemic and failing heart. Biochim Biophys Acta. 1813:1333–1350. 2011. View Article : Google Scholar : PubMed/NCBI
9	Lopaschuk GD, Barr R, Thomas PD and Dyck JRB: Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme a thiolase. Circ Res. 93:e33–e37. 2003. View Article : Google Scholar : PubMed/NCBI
10	Chen H and Xu Y: Clinical trial of trimetazidine combined with atorvastatin calcium in the treatment of coronary heart disease and angina pectoris with dyslipidemia. Zhongguo Lin Chuang Yao Li Xue Za Zhi. 32:966–968. 2016.(Chinese).
11	Zhou X and Huang H: Therapeutic effect of atorvastatin combined trimetazidine on blood lipids, inflammatory factors and cardiac function in patients with coronary heart disease. Chin J Cardiovasc Rehabil Med. 25:276–279. 2016.(Chinese).
12	Hardie DG, Ross FA and Hawley SA: AMPK: A nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol. 13:251–262. 2012. View Article : Google Scholar : PubMed/NCBI
13	Hardie DG: AMPK: Positive and negative regulation, and its role in whole-body energy homeostasis. Curr Opin Cell Biol. 33:1–7. 2015. View Article : Google Scholar : PubMed/NCBI
14	Ideta T, Shirakami Y, Miyazaki T, Kochi T, Sakai H, Moriwaki H and Shimizu M: The dipeptidyl peptidase-4 inhibitor teneligliptin attenuates hepatic lipogenesis via AMPK activation in non-alcoholic fatty liver disease model mice. Int J Mol Sci. 16:29207–29218. 2015. View Article : Google Scholar : PubMed/NCBI
15	Cheng S, Liang S, Liu Q, Deng Z, Zhang Y, Du J, Zhang Y, Li S, Cheng B and Ling C: Diosgenin prevents high-fat diet-induced rat non-alcoholic fatty liver disease through the AMPK and LXR signaling pathways. Int J Mol Med. 41:1089–1095. 2018.PubMed/NCBI
16	Smith BK, Marcinko K, Desjardins EM, Lally JS, Ford RJ and Steinberg GR: Treatment of nonalcoholic fatty liver disease: Role of AMPK. Am J Physiol Endocrinol Metab. 311:E730–E740. 2016. View Article : Google Scholar : PubMed/NCBI
17	Wang ZQ, Zhang XH, Yu Y, Tipton RC, Raskin I, Ribnicky D, Johnson W and Cefalu WT: Artemisia scoparia extract attenuates non-alcoholic fatty liver disease in diet-induced obesity mice by enhancing hepatic insulin and AMPK signaling independently of FGF21 pathway. Metabolism. 62:1239–1249. 2013. View Article : Google Scholar : PubMed/NCBI
18	Woods A, Williams JR, Muckett PJ, Mayer FV, Liljevald M, Bohlooly-Y M and Carling D: Liver-specific activation of AMPK prevents steatosis on a high-fructose diet. Cell Rep. 18:3043–3051. 2017. View Article : Google Scholar : PubMed/NCBI
19	Postic C, Dentin R, Denechaud P-D and Girard J: ChREBP, a transcriptional regulator of glucose and lipid metabolism. Annu Rev Nutr. 27:179–192. 2007. View Article : Google Scholar : PubMed/NCBI
20	Wang Y, Viscarra J, Kim S-J and Sul HS: Transcriptional regulation of hepatic lipogenesis. Nat Rev Mol Cell Biol. 16:678–689. 2015. View Article : Google Scholar : PubMed/NCBI
21	Saline M, Badertscher L, Wolter M, Lau R, Gunnarsson A, Jacso T, Norris T, Ottmann C and Snijder A: AMPK and AKT protein kinases hierarchically phosphorylate the N-terminus of the FOXO1 transcription factor, modulating interactions with 14-3-3 proteins. J Biol Chem. 294(35): 13106–13116. 2019.pii: jbc.RA119.008649. View Article : Google Scholar : PubMed/NCBI
22	Bandyopadhyay GK, Lu M, Avolio E, Siddiqui JA, Gayen JR, Wollam J, Vu CU, Chi NW, O'Connor DT and Mahata SK: Pancreastatin-dependent inflammatory signaling mediates obesity-induced insulin resistance. Diabetes. 64:104–116. 2015. View Article : Google Scholar : PubMed/NCBI
23	Zhao L, Zhang C, Luo X, Wang P, Zhou W, Zhong S, Xie Y, Jiang Y, Yang P, Tang R, et al: CD36 palmitoylation disrupts free fatty acid metabolism and promotes tissue inflammation in non-alcoholic steatohepatitis. J Hepatol. 69:705–717. 2018. View Article : Google Scholar : PubMed/NCBI
24	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-Delta DeltaC (T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
25	DeWeerdt S: Disease progression. Divergent paths. Nature. 551:S92–S93. 2017. View Article : Google Scholar : PubMed/NCBI
26	Michelotti GA, Machado MV and Diehl AM: NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol. 10:656–665. 2013. View Article : Google Scholar : PubMed/NCBI
27	Wong VW-S and Wong GL-H: A LEAN treatment for non-alcoholic steatohepatitis. Lancet. 387:628–630. 2016. View Article : Google Scholar : PubMed/NCBI
28	Kantor PF, Lucien A, Kozak R and Lopaschuk GD: The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res. 86:580–588. 2000. View Article : Google Scholar : PubMed/NCBI
29	Chen J, Lai J, Yang L, Ruan G, Chaugai S, Ning Q, Chen C and Wang DW: Trimetazidine prevents macrophage-mediated septic myocardial dysfunction via activation of the histone deacetylase sirtuin 1. Br J Pharmacol. 173:545–561. 2016. View Article : Google Scholar : PubMed/NCBI
30	Abdul-Wahed A, Guilmeau S and Postic C: Sweet sixteenth for ChREBP: Established roles and future goals. Cell Metab. 26:324–341. 2017. View Article : Google Scholar : PubMed/NCBI
31	Jump DB, Tripathy S and Depner CM: Fatty acid-regulated transcription factors in the liver. Annu Rev Nutr. 33:249–269. 2013. View Article : Google Scholar : PubMed/NCBI
32	Benhamed F, Denechaud P-D, Lemoine M, Robichon C, Moldes M, Bertrand-Michel J, Ratziu V, Serfaty L, Housset C, Capeau J, et al: The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans. J Clin Invest. 122:2176–2194. 2012. View Article : Google Scholar : PubMed/NCBI
33	Zhang Y, Hu SL, Hu D, Jiang JG, Cui GL, Liu XD and Wang DW: miR-1322 regulates ChREBP expression via binding a 3′-UTR variant (rs1051943). J Cell Mol Med. 22:5322–5332. 2018. View Article : Google Scholar : PubMed/NCBI
34	Xie X, Yan D, Li H, Zhu Q, Li J, Fang YP, Cheung CW, Irwin MG, Xia Z and Lian Q: Enhancement of adiponectin ameliorates nonalcoholic fatty liver disease via inhibition of FoxO1 in Type I Diabetic Rats. J Diabetes Res. 2018:62543402018. View Article : Google Scholar : PubMed/NCBI
35	O-Sullivan IS, Zhang W, Wasserman DH, Liew CW, Liu J, Paik J, DePinho RA, Stolz DB, Kahn CR, Schwartz MW, et al: FoxO1 integrates direct and indirect effects of insulin on hepatic glucose production and glucose utilization. Nat Commun. 6:70792015. View Article : Google Scholar : PubMed/NCBI